Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MTOR”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02451696
What this trial is testing

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

Who this might be right for
EpilepsyTuberous Sclerosis ComplexFocal Cortical Dysplasia
NYU Langone Health 15
Not applicableStudy completedNCT00636090
What this trial is testing

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Duke University 35
Large-scale testing (Phase 3)Study completedNCT01707849
What this trial is testing

The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation

Who this might be right for
Hepatitis C Recurrence After Liver Transplant
Hospital Vall d'Hebron 18
Early research (Phase 1)Study completedNCT00574366
What this trial is testing

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 14
Early research (Phase 1)Looking for participantsNCT07369505
What this trial is testing

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Who this might be right for
Breast Cancer MetastaticRenal Cell Carcinoma (RCC)Neuroendocrine Tumors+2 more
SAPU NANO (US) LLC 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07680322
What this trial is testing

The Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy

Who this might be right for
Tuberous Sclerosis ComplexEpilepsy
Aeovian Pharmaceuticals, Inc. 42
Early research (Phase 1)Temporarily pausedNCT03065062
What this trial is testing

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Who this might be right for
Lung Cancer Squamous CellSolid TumorsHead & Neck Cancer+1 more
Dana-Farber Cancer Institute 75
Testing effectiveness (Phase 2)Study completedNCT01275222
What this trial is testing

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Who this might be right for
Gastrointestinal Stromal Tumors
Novartis Pharmaceuticals 117
Very early researchWithdrawnNCT04019769
What this trial is testing

Glutamine Supplementation in People With Immune Dysregulation

Who this might be right for
EczemaMTOROC1 Signaling
National Institute of Allergy and Infectious Diseases (NIAID)
Testing effectiveness (Phase 2)UnknownNCT04998760
What this trial is testing

Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )

Who this might be right for
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
Qi Zhou 96
Early research (Phase 1)Not Yet RecruitingNCT07667413
What this trial is testing

Topical TOR-582 Treatment of Epistaxis in HHT

Who this might be right for
Hereditary Hemorrhagic Telangiectasia (HHT)Epistaxis
Columbia University 27
Testing effectiveness (Phase 2)WithdrawnNCT01658176
What this trial is testing

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer
Early research (Phase 1)WithdrawnNCT02833506
What this trial is testing

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+18 more
Roswell Park Cancer Institute
Early research (Phase 1)Study completedNCT02619864
What this trial is testing

MTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Who this might be right for
Glioblastoma Multiforme
Canadian Cancer Trials Group 15
Very early researchLooking for participantsNCT07065552
What this trial is testing

Tirzepatide in Obesity-Driven Endometrial Cancer

Who this might be right for
Endometrial CancerObesity
UNC Lineberger Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07081763
What this trial is testing

Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

Who this might be right for
HIV-1-infection
ANRS, Emerging Infectious Diseases 191
Post-approval studies (Phase 4)Ended earlyNCT01561404
What this trial is testing

Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise

Who this might be right for
Disorder Related to Renal TransplantationExercise, AerobicMuscle Strength
Josep M Cruzado 3
Large-scale testing (Phase 3)Study completedNCT00863655
What this trial is testing

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 724
Early research (Phase 1)Ended earlyNCT00742105
What this trial is testing

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Who this might be right for
CancerSolid TumorAdvanced Solid Tumor
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT00459186
What this trial is testing

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Who this might be right for
Metastatic, Androgen Independent Prostate CancerProstate Cancer
Dana-Farber Cancer Institute 19
Next Page